BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 7, 2026
Home » Blogs » BioWorld MedTech Perspectives » Elekta provides LINC to innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Elekta provides LINC to innovation

Nov. 11, 2013
By Omar Ford

The first thing that hits you when you walk in Elekta's Learning and Innovation Center (LINC) located in Atlanta, is that there is a lot of history here.

Elekta3

From the Leksell Stereotactic System invented in 1949, to the Leskell Gamma Knife Perfexion - the advances in med-tech through the lens of a once small but now sizeable company are evident.

But to merely think of this as a repository of the firm's greatest technological achievements and advancements in the treatment of cancer would be egregiously wrong. LINC is a learning center that links the past to future innovation.

DSCN0013The 25,000 square foot facility that boasts lecture rooms and all of the firm's latest technology is instead a learning destination. LINC was launched during the American Society for Radiology (Fairfax, Virginia) meeting held in Atlanta in September. Last month, Medical Device Daily toured the facility, which boasts some of the companies flagship technology, such as the new Versa HD linear accelerator and Leksell Gamma Knife Perfexion. Enhancing the experience, students have access to the Versa HD vault, which is large enough for hands-on learning. Elektaphoto1

"Elekta's really putting forward education and training for patient safety as a first priority," Ian Dickson, Elekta's CFO, told Medical Device Daily. "The company has grown so rapidly in the last four or five years – there's been a lot of organic growth but also through acquisition. Our education programs are pretty dispersed around the U.S. so we saw this to really get the value proposition and to put safe training and education on the map for us as an organization into the radiation community we needed to centralize it, and that's what we did by bringing it here into the Perimeter area here in Atlanta."

Elekta4Simply put, Elekta is on the right path to innovation. You can't go forward without investing in the future of your technology.  Giving healthcare professionals the advanced training that they might need on Elekta's wide array of products accomplishes that goal.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 6, 2026.
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing